Stock Price & Analysis

The S1 support level for MREO Stock is $2.57 ,The R1 resistant level for MREO Stock is $2.99.

As of the end of day on 2025-02-26, the price of MREO Stock was $2.45.

The target price for MREO Stock according to analyst rating is 7.50, with the highest price target at 10.00 and the lowest at 6.00. Analysts have a Strong Buy rating on MREO Stock overall.

The market cap of MREO is $380.1M.

Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

MREO has a total of 36 employees.